Gynecologic Cancer News
Olaparib Treatment May Improve Health-Related Quality of Life in Germline BRCA1/2-Mutated Ovarian Cancer
Olaparib, may help to improve duration of good quality of life and quality-adjusted progression-free survival in germline BRCA1/2-mutated ovarian cancer.
The US Preventive Services Task Force conducted a review of trials and cohort studies to support an update of its cervical cancer screening recommendations for women ages 21 to 65 and older.
For cancers associated with numerous copy number changes, it is difficult to assign disease classifiers and identify useful targets for drug development.
Previous studies have suggested that analgesic medicine use may have a protective effect for patients with ovarian cancer.
The confirmation of a positive HPV test appeared to be more predictive of a grade 2 or 3 cervical lesion than cytology screening alone.
Pembrolizumab is the first anti-PD-1 therapy approved for the treatment of advanced cervical cancer.
It was suggested that estrogen alone may have a protective effect, decreasing the risk of breast cancer by 8% with every year of use.
The researchers enrolled 25 platinum-pretreated, immunotherapy-naïve patients with recurrent advanced epithelial ovarian cancer (EOC) for the trial.
Mice treated with 2-94 had few or no signs of lymphopenia or neutropenia, common adverse events associated with palbociclib.
Per-cycle, PLD cost $2509, bevacizumab cost $7585, and pembrolizumab cost $9026.
p53 mutational status may be a viable strategy upon which to base the course of therapy.
There were no significant differences in patterns of recurrence in the chemotherapy vs CCRT groups.
Researchers randomly assigned 74 patients to receive everolimus plus letrozole daily or tamoxifen daily plus medroxyprogesterone daily on alternating weeks.
Previous epidemiological studies have indicated inconsistent results regarding the correlation between antidepressant use and ovarian cancer risk.
Researchers have found 3 major predictors for survival: tumor infiltrating leukocytes (TIL), programmed death-ligand 1 (PD-L1) expression, and mutational burden.
Ovarian cancer risk is known to be increased by BRCA1 and BRCA2 gene mutations, but recent developments have led researchers to believe there are several genes involved in homologous recombination-mediated DNA damage.
Bevacizumab-awwb is a recombinant IgG1 monoclonal antibody that works by binding to vascular endothelial growth factor (VEGF) and inhibits angiogenesis.
Eligible patients had platinum-sensitive malignancies, had at least 2 previous platinum-based therapies, and had reached complete or partial response to the most recent platinum-based regimen.
First-line treatment failed to improve progression-free survival among women of European descent with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma (EOC).
Researchers examined the differences in outcomes in patients with ovarian cancer who received platinum-based chemotherapy and non-platinum based chemotherapy after relapse.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|